Pfizer has agreed to acquire Metsera, a biotech company focused on weight loss treatments, in a deal valued at up to $7.3 billion. This acquisition comes after Pfizer faced challenges with its own obesity drug candidates, leading to the discontinuation of its lead drug due to safety concerns. Metsera, founded in 2022, has a diverse pipeline of oral and injectable obesity treatments, including a GLP-1 drug that demonstrated an 8.4% weight loss in early trials. The deal includes an initial cash payment of $47.50 per share, representing a 43% premium over Metsera's recent closing price. Analysts estimate that Metsera's candidates could generate over $5 billion in peak annual sales, highlighting the lucrative potential of the obesity drug market, which could reach $100 billion by the 2030s. Pfizer aims to leverage its expertise to accelerate the development of Metsera's promising treatments.